Drilldown: Medicines
Medicines > classes 
:
Dissociative or
Phenethylamine or
[[:Category:Antimuscarinics|Antimuscarinic (M3-selective)]]
:
Dissociative or
Phenethylamine or
[[:Category:Antimuscarinics|Antimuscarinic (M3-selective)]] Use the filters below to narrow your results.
generic:
brand:
classes: (Click arrow to add another value)
mechanism:
None (1) ·
5-HT2A agonist (12) ·
5-HT2A agonist; long duration (1) ·
5-HT2A agonist; MAO inhibitor (1) ·
5-HT2A agonist; milder than other 2C-x (1) ·
5-HT2A partial agonist (1) ·
Active metabolite of DXM; NMDA antagonist (1) ·
Contains salvinorin A (1) ·
Extremely potent 5-HT2A agonist; vasoconstrictor (1) ·
Extremely potent 5-HT2A agonist; very long duration (1) ·
Kappa-opioid agonist; NMDA antagonist; SERT/DAT/NET inhibitor (1) ·
Kappa-opioid receptor agonist (1) ·
NMDA antagonist (3) ·
NMDA antagonist; endogenous opioid releaser (1) ·
NMDA antagonist; fluorinated ketamine analogue (1) ·
NMDA antagonist; kappa-opioid agonist (1) ·
NMDA antagonist; ketamine analogue (1) ·
NMDA antagonist; more stimulating than PCP (1) ·
NMDA antagonist; opioid agonist (1) ·
NMDA antagonist; potent opioid agonist (1) ·
NMDA antagonist; SERT inhibitor; sigma-1 agonist (1) ·
NMDA antagonist; sigma receptor agonist (2) ·
NMDA antagonist; sigma receptor agonist; dopaminergic (1) ·
NMDA antagonist; sigma-1 agonist; serotonin reuptake inhibitor (1) ·
Potent 5-HT2A agonist (5) ·
Potent 5-HT2A agonist; no oral activity (1) ·
Potent 5-HT2A agonist; very long duration (1) ·
Very potent 5-HT2A agonist; long duration (1) ·
'"`UNIQ--vote-00000DFA-QINU`"' CYP3A4 substrate; QT-interval prolongation has been reported at higher doses. Like other antimuscarinics, contributes to cumulative anticholinergic burden in older adults'"`UNIQ--ref-00000DFB-QINU`"'. (1)
uses:
None (45) ·
Treatment-resistant depression (TRD) in adults, as adjunct to oral antidepressant (FDA-approved March 2019). Depressive symptoms in adults with MDD with acute suicidal ideation or behavior (FDA-approved Aug 2020). (1) ·
'"`UNIQ--vote-00000DFC-QINU`"', '"`UNIQ--vote-00000DFD-QINU`"' (1)
starting dose:
None (45) ·
5 mg PO once daily; titrate to 10 mg after 2 weeks if needed (1) ·
Induction (TRD): 56 mg intranasal twice weekly × 4 weeks. Maintenance: 56-84 mg once weekly × 4 weeks, then 56-84 mg every 1-2 weeks. For acute suicidality: 84 mg twice weekly × 4 weeks. Administered under medical supervision in REMS-certified site. (1)
preparations:
fda max:
routes:
onset:
duration:
halflife:
bioavailability:
pregnancy:
Showing below up to 47 results in range #1 to #47.